Boston Scientific Corporation BSX | NYSE

$41.98 -$1.01 | -2.35%
TREND SIGNAL:Signal available — unlock to view |2026-08-28

Company Overview:

Market Cap: $61.78B
Trailing PE: 17.8x
FWD PE *: 13.6x
Payout Ratio (TTM): —
52-Week Range: $39.57 - $101.91

* Forward PE is based on street estimates.

10 Year BSX Performance Metrics:

Total Return (with DRIP): 101.4% (7.26% CAGR)
Total Return (no DRIP): 101.4% (7.26% CAGR)
Share Price: 101.4% (7.26% CAGR)
Yield on Cost (with DRIP): —
Total Invested: $10,000
Total Value (with DRIP): $20,144
Total Return $ (with DRIP): $10,144
BSX Total Return
1M 3M 6M YTD 1Y 3Y 5Y 10Y
BSX Price Chart
1M 3M 6M YTD 1Y 3Y 5Y 10Y All
Build Custom Charts
BSX - Chart 1
BSX - Chart 2
BSX - Chart 3

BSX Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

Revenue
BSX Revenue CAGR:1Y: 1.44%2Y: 10.49%5Y: 11.87%10Y: 9.33%
Earnings Per Share (EPS)
BSX EPS CAGR:1Y: -21.57%2Y: 12.63%5Y: 6.64%10Y: 8.93%
Net Income
BSX Net Income CAGR:1Y: -23.44%2Y: 11.01%5Y: 7.37%10Y: 9.75%
EBITDA
BSX EBITDA CAGR:1Y: -28.59%2Y: -3.81%5Y: 3.51%10Y: 7.99%
Free Cash Flow
BSX Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Free Cash Flow / Share
BSX Free Cash Flow / Share CAGR:1Y: -23.60%2Y: 12.43%5Y: 18.97%10Y: 0.00%
Operating Income
BSX Operating Income CAGR:1Y: -6.76%2Y: 20.52%5Y: 20.40%10Y: 10.90%
Gross Profit
BSX Gross Profit CAGR:1Y: -3.22%2Y: 13.78%5Y: 11.18%10Y: 8.68%
Shares Outstanding
BSX Shares Outstanding CAGR:1Y: -2.91%2Y: -1.20%5Y: 0.23%10Y: 0.51%
Share Buybacks
BSX Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Stock-Based Comp
BSX Stock-Based Comp CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Expenses
BSX Expenses CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Revenue vs Net Income
EPS vs FCF / Share
EPS vs PE Ratio
FCF vs FCF / Share
FCF vs Stock Based Comp
Cash & Debt
Revenue by Segment
BSX Revenue CAGR:1Y: 1.44%2Y: 10.49%5Y: 11.87%10Y: 9.33%
Revenue by Region
BSX Revenue CAGR:1Y: 1.44%2Y: 10.49%5Y: 11.87%10Y: 9.33%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

REVENUE: Actual + Estimates
BSX Actual Revenue CAGR:1Y: 1.44%2Y: 10.49%5Y: 11.87%10Y: 9.33%
EPS: Actual + Estimates
BSX Actual EPS CAGR:1Y: -21.57%2Y: 12.63%5Y: 6.64%10Y: 8.93%
NET INCOME: Actual + Estimates
BSX Actual Net Income CAGR:1Y: -23.44%2Y: 11.01%5Y: 7.37%10Y: 9.75%
EBITDA: Actual + Estimates
BSX Actual EBITDA CAGR:1Y: -28.59%2Y: -3.81%5Y: 3.51%10Y: 7.99%

Ratios, Profit Margins & Return on Capital:

Net Profit Margin
BSX Net Profit Margin CAGR:1Y: -24.55%2Y: 0.49%5Y: -4.02%10Y: 0.38%
Gross Profit Margin
BSX Gross Profit Margin CAGR:1Y: -4.59%2Y: 2.98%5Y: -0.62%10Y: -0.60%
Price to Earnings
BSX Price to Earnings CAGR:1Y: -43.00%2Y: -35.60%5Y: -6.48%10Y: -2.60%
Price To Sales Ratio
BSX Price To Sales Ratio CAGR:1Y: -56.91%2Y: -35.21%5Y: -10.20%10Y: -2.21%
Return on Capital Employed
BSX Return on Capital Employed CAGR:1Y: -11.72%2Y: 8.79%5Y: 12.28%10Y: 0.45%
Return on Invested Capital
BSX Return on Invested Capital CAGR:1Y: -14.39%2Y: 17.01%5Y: 8.10%10Y: -3.00%

Compare stocks side-by-side

Projected Future Returns & Dividends for BSX

Based on past 10-year performance, here are BSX growth metrics:

Share price CAGR of +6.94%
Dividend CAGR of +0%

Using BSX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

BSX (DRIP)BSX - No DRIP
Current Price$41.98$41.98
Start Shares238.21238.21
Start Value$10,000$10,000
  
After 10 years:
Final Share Count238.21238.21
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$41.98$41.98
Total Dividends$0$0
Final Value$10,000$10,000

Estimated Future Value + Dividends - BSX

NOTE: Above numbers are our estimate based on BSX's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Company Info

Boston Scientific Corporation (BSX) had its IPO on 1992-05-19, and is traded on NYSE stock exchange.

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

BSX website: https://www.bostonscientific.com


Loading signals…

DCF Model — BSX

Value from:
Pay up to today
—
vs current price $41.98
—
Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
YearFCFImplied price
Sensitivity — fair value: growth ↓ × target return →